The study provides the first atomic description of the herpes virus associated with Kaposi's sarcoma, allowing scientists to identify specific targets for antiviral therapies. This breakthrough could lead to the development of new treatments for both KSHV and Epstein-Barr viruses.
Researchers at The Scripps Research Institute have discovered the workings of a promising treatment for Marburg virus, which has a mortality rate of up to 88 percent. The treatment, MR191, targets a conserved site on the virus and neutralizes it by mimicking the host receptor.
Researchers have discovered a way to prevent the Ebola virus from spreading by inhibiting a specific enzyme that allows it to copy itself. By blocking this enzyme, the virus's ability to produce more infection is reduced, suggesting potential breakthrough in treatment.
Researchers found that Ebola survivors' immune systems may provide some protection against future infection. The study, led by UCLA, located 14 survivors of the 1976 outbreak who still lived in the same remote villages.
A study found that lactic acid bacteria can protect against different subtypes of influenza A virus, resulting in reduced weight loss and lower amounts of virus replication in the lungs. The researchers used a heat-killed strain of Lactobacillus casei DK128 to pretreat mice before infecting them with the virus.
A new report highlights how the King's Sierra Leone Partnership joined forces with local mental health professionals to improve psychiatric healthcare during the 2014 Ebola outbreak. The partnership created a nurse-led mental health and psychosocial support service, strengthening skills of non-specialist nurses, which led to the establ...
A research team led by the University of Wisconsin-Madison has identified 11 biomarkers that distinguish fatal Ebola infections from nonfatal ones. These biomarkers may aid in future treatment efforts and help clinicians prioritize scarce resources for the sickest patients.
Scientists from the German Center for Infection Research found that the Zika virus has a high seroprevalence rate in Salvador, northeastern Brazil, suggesting that further outbreaks are unlikely. The study linked this finding to increased population immunity and socioeconomic factors such as poverty.
Scientists have identified two biomarkers that accurately predict patient survival in Ebola cases. The study analyzed blood samples from survivors and fatal cases, revealing distinct metabolic responses and immune-related molecules. These findings could improve treatment allocation and patient outcomes.
Researchers found that people generalize knowledge from similar animals to those they encounter, leading to increased risk perception. This study highlights the importance of understanding inductive reasoning in health communication and its potential impact on public health.
Researchers discover nearly perfect genetic transmission of the virus from a father to his son, suggesting that HSV-1 may not change much when transmitted between closely related individuals. However, transmission between unrelated hosts may provide an opportunity for greater genetic diversity and potential changes in virulence.
A study published in JAMA found a strong association between Zika virus infection and Guillain-Barré syndrome in Puerto Rico. The study identified acute Zika virus infection as a significant risk factor for GBS, highlighting the need for further investigation into the pathophysiology of Zika virus infection.
After a 10-year absence, Usutu virus has reemerged in both blackbirds and humans, particularly in Austria and Hungary. Genetic analysis reveals that the viruses circulating in these regions are closely related to those found in Italy, demonstrating inter-country transmission of viral strains.
A new study assesses pandemic potential in Africa prior to outbreaks, mapping vulnerabilities to mitigate the spread of Ebola and other deadly viruses. Researchers identify high-risk locations, including parts of Central African Republic, Chad, Somalia, and South Sudan, highlighting the need for targeted preparedness activities.
Two Ebola vaccine candidates elicited strong and long-lasting immune responses in a randomized, placebo-controlled trial. The study found that 71% of one vaccine and 84% of another developed antibodies to the Ebola virus within a month, with antibody responses maintained for at least a year.
Scientists develop an antibody-based Zika virus therapeutic that protects monkeys from infection and neutralizes the virus. The treatment has been shown to be effective in preventing Zika virus replication in rhesus macaques.
Researchers at the University of Nebraska-Lincoln have identified a Zika virus mutation that contains a sugar in its protein envelope, which may help the virus enter the brain. This discovery could explain why the virus became more lethal during outbreaks in the Caribbean and South America.
The University of Hawaii has received a nearly $6.3 million grant to develop a heat-stable, trivalent Ebola vaccine that can protect against three related viruses in the same family. The vaccine, developed by Axel Lehrer, PhD, has the potential to speed up protection for health workers and others during outbreaks.
Researchers at the University of Hawaii aim to develop strategies to prevent Zika virus transmission to the fetus and treat patients infected with the virus. Dr. Mukesh Kumar will work on understanding how the virus is transmitted and developed effective therapeutics.
Researchers found that the Ebola virus exploits a protein called Tim-1 in T-cells to spread and cause disease. The study suggests that blocking this protein could lead to effective treatments for Ebola.
Scientists have discovered that the Ebola virus directly interacts with T-cells and specifically Tim-1, triggering a cytokine storm. This study provides new insights into the mechanisms of Ebola infection and offers potential targets for therapeutic strategies to reduce the severity of the disease.
Researchers found utilizing local artists' images and dialects helped address misperceptions about Ebola treatment, involving trusted messengers for two-way communication. The study's evidence-based approach can inform message development and implementation during public health emergencies.
Researchers from Instituto de Medicina Molecular created a chimera virus that can test molecules to treat cancers caused by human herpes virus infection in mice models of disease. This finding preserves the functionality of LANA, a protein vital for Kaposi virus maintenance, allowing new cancer treatments to be developed.
Researchers identified a signature of five early innate immune markers correlating with antibody titers after vaccination, providing insight into VSV-based vaccine efficacy. The study's findings could lead to accelerated vaccine development and improved emergency vaccine strategies.
A new study found that Zika virus preferentially replicates in the female reproductive tract after vaginal transmission, suggesting a higher risk of fetal Zika disease. The research used rhesus macaques to investigate the effects of mosquito and sexual transmission on Zika infection.
Researchers at NIH's National Institute of Allergy and Infectious Diseases have developed a laboratory model to study tick-borne flaviviruses, including Powassan virus. The new model involves culturing organs from Ixodes scapularis ticks with flaviviruses, which can infect salivary glands and midgut.
Researchers have identified a potential method to screen for Zika virus exposure using proteomics in saliva. The study found that specific protein signatures can be detected in the saliva of infected individuals, allowing for earlier detection and treatment of the virus.
Researchers from the University of Exeter have discovered a virus that can reprogram ocean plankton to absorb certain nutrients, potentially affecting carbon storage in the ocean. The study found that infected phytoplankton cells become more competitive and grow faster before being killed by the virus.
A recent study published in the Journal of Virology has pinpointed how a tiny protein speeds up Ebola's contagiousness. The researchers identified that the delta peptide weakens protective membranes in gastrointestinal cells, allowing viruses to enter and wreak havoc.
Researchers Kartik Chandran and Jonathan Lai will develop broadly active monoclonal antibody therapies for Ebola and extend the strategy to Marburg virus. They will also investigate how hantaviruses enter the human body.
Researchers have developed a mouse model to study Zika virus transmission, finding that the virus can be transmitted sexually from males to females and vertically from pregnant women to their fetuses. The study suggests that the placenta may be a key barrier in preventing Zika virus infection of the fetus.
Researchers at the University of North Carolina Health Care found that Ebola virus RNA can persist in the semen of survivors for more than two years after infection. This persistence has important implications for transmission and may require an update to World Health Organization guidelines.
A new antibody-based assay developed by researchers at UC Berkeley and Humabs BioMed has shown very high sensitivity and specificity in distinguishing Zika virus infections from those caused by similar viruses. The test is simple, cost-effective, and can be used to detect both recent and past Zika virus infections.
Researchers analyzed cerebrospinal fluid from Ebola survivors and found no viral RNA, but the results may suggest potential for dormant virus transmission. The findings highlight the need for monitoring EVD survivors for neurologic symptoms suggesting relapse in the CNS.
Researchers have found that Ebola virus can persist in specific areas of the body, including the eye, brain, and testes, even after symptoms resolve. This knowledge holds promise for developing medical products to counter the disease in humans.
Researchers studied the relationship between an African forest bat, a novel virus, and a parasite, identifying all three as potentially new species. The study found that the parasite plays a crucial role in transmitting the virus, with the fly serving as a 'chauffeur' to help the virus spread.
Tulane University has received a $12 million grant to test a promising drug treatment for Lassa fever and develop a vaccine against the deadly disease. The vaccine targets a recently discovered key antibody target on the surface of the virus, which can block it from infecting host cells.
Researchers have developed virus-derived expression vectors as a potential gene therapy vehicle for treating various diseases. These vectors use viral sequences to silence specific genes or induce RNA interference, effectively downregulating viral replication and expressing therapeutic proteins.
A phase 1 randomized controlled trial found an Ebola virus disease vaccine developed in Canada to be well-tolerated and effective, with high antibodies present six months after immunization. The vaccine showed no safety concerns and was well-received by participants.
In response to the ongoing Ebola outbreak in the Democratic Republic of Congo (DRC), RTI International is working closely with the Ministry of Health and other partners to strengthen local surveillance systems. The average case fatality rate for Ebola is around 50%, and there have been over 100 contacts under daily monitoring.
Researchers at Argonne National Laboratory used X-ray crystallography to solve the structure of Lassa virus glycoprotein, a key component in vaccine development. The study provides valuable insights into how the virus enters human cells, paving the way for the design of an effective vaccine.
Researchers at Tulane University have identified a possible explanation for the rapid spread of the Ebola virus, pinpointing a small protein as the culprit. The delta peptide, produced in large amounts during infection, damages host cells and may contribute to severe gastrointestinal symptoms, leading to high mortality rates.
Researchers discuss routes of Zika virus transmission and its effects on pregnancy outcomes, including miscarriage and microcephaly. Therapeutic approaches aimed at blocking Zika virus transmission from mother to fetus are also presented.
A new Zika virus vaccine has shown 100% protection in mice, utilizing the NS1 protein. The vaccine's effectiveness was demonstrated through a single-dose immunization strategy.
A team led by Kathryn Hastie and Erica Ollmann Saphire at The Scripps Research Institute has solved the structure of Lassa virus's surface glycoprotein, a key step in developing a vaccine. The breakthrough provides a blueprint to design a Lassa virus vaccine, which could help combat the deadly arenavirus family.
A study by a multi-national research team, including scientists from the US Army Medical Research Institute of Infectious Diseases, explains how Zika virus entered the US and how it might re-enter the country. They used near real-time genomic sequencing to create a family tree showing the virus's spread through space and time.
Researchers analyzed 174 Zika virus genomes from patient and mosquito samples to reconstruct the virus's spread across South and Central America. The study suggests that Zika was circulating in Brazil around February 2014, months before local cases were detected.
Researchers found that Ebola virus binds directly to white blood cells, causing their death and disrupting the immune system. This study provides new insights into the mechanisms of Ebola infection and may lead to the development of targeted therapies for Ebola virus disease.
Scientists have identified two natural human antibodies that can neutralize all five known ebolaviruses, offering a breakthrough in the fight against these deadly viruses. The antibodies work by interfering with the virus's ability to infect cells, preventing it from multiplying and causing disease.
A Canadian researcher has received a $3.99 million grant to develop an HIV vaccine candidate in partnership with IAVI. The team aims to improve upon a promising candidate and advance it to clinical testing in human volunteers.
Researchers aim to use Zika virus to target glioblastoma, the most common and aggressive form of brain tumour. The virus can cross the blood-brain barrier, sparing healthy tissue and opening a potential new way to attack the disease.
Scientists identified two human antibodies that neutralize multiple ebolavirus species, offering potential treatments for people infected with Ebola virus or related viruses. These broadly protective antibodies could provide a basis for therapeutic pan-ebolavirus antibody treatments and vaccines.
Researchers successfully synthesized Zika virus from a viral sequence detected in infected tissue, allowing them to induce microcephaly in pregnant mice and study its transmission by mosquitoes. This breakthrough helps advance research into the mysterious emergence of Zika virus, which causes devastating foetal brain infections.
A new study found that responders to the West African Ebola epidemic showed little evidence of infection, with 99% showing no signs. Despite reported near-miss exposures and symptoms, many respondents were not tested for Ebola virus at the time, highlighting the need for standardized protocols.
A new study published in PLOS Medicine found that undiagnosed Ebola virus infection was probably very rare among international healthcare workers deployed during the 2013-2015 outbreak. Despite asymptomatic cases occurring, no evidence of missed infections was found, but 'near miss' exposure incidents were common, putting frontline wor...
A new management approach developed by an international team of researchers, including the University of Warwick, helps to streamline outbreak decision-making. The approach identifies two effective strategies: reducing transmission rates at funerals and in communities, such as educating people about disease transmission.
Researchers found that around 15% of Ebola survivors have distinctive retinal scars, which appear specific to the disease but spare vision. The study also suggests that aqueous fluid analysis can help diagnose Ebola eye disease and enable access to cataract surgery for affected survivors
A new detection test for Zika virus distinguishes between African and Asian strains, improving tracking efforts. The low-cost LAMP test is faster than current gold-standard methods, with minimal processing requirements.
The study found that Zika virus can persist in cerebrospinal fluid, lymph nodes, and colorectal tissue of infected rhesus monkeys for up to 42 days and 72 days respectively. The virus persistence may contribute to neurological issues associated with Zika infection in humans.
Researchers have identified early plasma cytokine signatures that correlate with and predict the immunogenicity and reactogenicity of vaccines based on living viruses. This breakthrough can inform and accelerate rational development of new vaccines, especially during outbreaks and epidemics.